Vision RT reins in £250,000 for US push:
This article was originally published in Clinica
Executive Summary
London, UK-based 3D imaging specialist Vision RT has secured £250,000 ($504,000) in financing from new investor The Capital Fund in a bid to support its operations in the US. "We have recently appointed a director of sales, North America, who is establishing a direct sales and marketing presence for us in the US," company founder and CEO Dr Norman Smith told Clinica. The investment, which is part of a larger financing round, will also be used to further develop the company's patent-pending technology, the GateCT and GateRT 3D tracking platforms.
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.